ADMA Biologics Inc (NASDAQ:ADMA) rose 10.5% during trading on Friday . The company traded as high as $4.41 and last traded at $4.22. Approximately 1,011,871 shares were traded during mid-day trading, an increase of 75% from the average daily volume of 578,283 shares. The stock had previously closed at $3.82.
ADMA has been the topic of a number of analyst reports. HC Wainwright initiated coverage on ADMA Biologics in a research report on Tuesday, October 30th. They issued a “buy” rating and a $17.00 price target on the stock. Oppenheimer set a $13.00 target price on ADMA Biologics and gave the company a “buy” rating in a research report on Monday, November 12th. Finally, Maxim Group set a $12.00 target price on ADMA Biologics and gave the company a “buy adma” rating in a research report on Thursday, December 20th. Seven research analysts have rated the stock with a buy rating, ADMA Biologics has an average rating of “Buy” and an average price target of $10.42.
The company has a quick ratio of 4.92, a current ratio of 6.32 and a debt-to-equity ratio of 1.11. The stock has a market cap of $166.86 million, a P/E ratio of -2.21 and a beta of 2.88.
ADMA Biologics Company Profile (NASDAQ:ADMA)
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Featured Article: SEC Filing
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.